Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

206.27 -2.68 (-1.28%)
Streaming Delayed Price Updated: 4:00 PM EST, Mar 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 260,159
Open 206.43
Bid (Size) 190.00 (200)
Ask (Size) 300.00 (100)
Prev. Close 208.95
Today's Range 199.00 - 208.87
52wk Range 93.58 - 212.49
Shares Outstanding 16,676,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Ligand Pharma (LGND) Earnings Call Transcript ↗
Ligand Pharma (LGND) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Ligand Pharmaceuticals (NASDAQ:LGND) Beats Q4 Estimates and Reaffirms 2026 Guidance ↗
Via Chartmill

Performance

YTD
+8.5%
+8.5%
1 Month
+3.7%
+3.7%
3 Month
+9.4%
+9.4%
6 Month
+23.0%
+23.0%
1 Year
+78.7%
+78.7%

More News

Read More
News headline image
The Great Rotation: Small-Caps Break the Mega-Cap Monopoly in Early 2026
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
This $38.8 Million Vicor Bet Is Getting Bigger Amid a 200% Stock Surge ↗
Via The Motley Fool
News headline image
Sportradar Stock Down 26%, but One Fund Just Disclosed a New $12.6 Million Stake ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What Investors Should Know as One Fund Sells $11 Million of Cavco Industries Stock ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Fund Sells $23 Million in Globalstar as Stock Surges 170% in One Year ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Chime Is Down 27% From Its IPO Price, Yet Posting 29% Revenue Growth: Why This New $15 Million Bet Stands Out ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Solaris Stock Is Up 100% This Past Year, and One Fund Is Betting $29 Million on More Growth ↗
Via The Motley Fool
Topics Energy
News headline image
Stock Up 40% in a Year, $706 Million in Quarterly Sales: Why Boot Barn’s Trimmed Stake Deserves a Look ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗
Via Investor's Business Daily
News headline image
This Fund Sold $9 Million of Ligand Stock After an 84% Rally — What Investors Should Know ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why One Small-Cap Fund Bought $11 Million in Cellebrite Stock Last Quarter ↗
Via The Motley Fool
News headline image
This Fund Cut $7.3 Million of Atlas Energy Stock as the Company Suspends Its Dividend to Help Fuel Growth ↗
Via The Motley Fool
Topics Economy Regulatory Compliance
News headline image
Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
News headline image
EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch ↗
Via Benzinga
News headline image
Ligand (LGND) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
Via MarketMinute
Topics Intellectual Property
News headline image
Ligand Pharmaceuticals (NASDAQ:LGND) Surges on Strong Q3 2025 Earnings Beat and Raised Guidance ↗
Via Chartmill
Topics Earnings
News headline image
What's Next: Ligand Pharmaceuticals's Earnings Preview ↗
Via Benzinga
News headline image
Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
What Analysts Are Saying About Ligand Pharmaceuticals Stock ↗
Via Benzinga
News headline image
Ligand (LGND) Q2 Revenue Jumps 15% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Ligand Pharmaceuticals (NASDAQ:LGND) Surpasses Q2 2025 Earnings Estimates with Strong Royalty Growth ↗
Via Chartmill

Frequently Asked Questions

Is Ligand Pharmaceuticals Incorporated - Common Stock publicly traded?
Yes, Ligand Pharmaceuticals Incorporated - Common Stock is publicly traded.
What exchange does Ligand Pharmaceuticals Incorporated - Common Stock trade on?
Ligand Pharmaceuticals Incorporated - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ligand Pharmaceuticals Incorporated - Common Stock?
The ticker symbol for Ligand Pharmaceuticals Incorporated - Common Stock is LGND on the Nasdaq Stock Market
What is the current price of Ligand Pharmaceuticals Incorporated - Common Stock?
The current price of Ligand Pharmaceuticals Incorporated - Common Stock is 206.27
When was Ligand Pharmaceuticals Incorporated - Common Stock last traded?
The last trade of Ligand Pharmaceuticals Incorporated - Common Stock was at 03/05/26 04:00 PM ET
What is the market capitalization of Ligand Pharmaceuticals Incorporated - Common Stock?
The market capitalization of Ligand Pharmaceuticals Incorporated - Common Stock is 3.44B
How many shares of Ligand Pharmaceuticals Incorporated - Common Stock are outstanding?
Ligand Pharmaceuticals Incorporated - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.